Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry.

Xiao X WeiLucia KwakAnis HamidMonica HeChristopher J SweeneyScott C FlandersMatthew HarmonAtish D Choudhury

Published in: Prostate cancer and prostatic diseases (2022)

In this analysis of mCRPC patients treated with sipuleucel-T who did not immediately initiate subsequent therapy using two datasets, delayed PSA response was observed in a subset of patients indicating delayed clinical activity.

Keyphrases

end stage renal disease
prostate cancer
newly diagnosed
ejection fraction
squamous cell carcinoma
chronic kidney disease
small cell lung cancer
peritoneal dialysis
stem cells
type diabetes
cell therapy
patient reported outcomes
rna seq
single cell
smoking cessation